NUS and A*STAR researchers develop wearable, stretchable sensor for quick, continuous, and non-invasive detection of solid-state skin biomarkers

Detecting diseases early requires the rapid, continuous and convenient monitoring of vital biomarkers. Researchers from the National University of Singapore and the Agency for Science, Technology and Research have developed a novel sensor that enables the continuous, and real-time detection of solid-state epidermal biomarkers, a new category of health indicators. The team’s wearable, stretchable, hydrogel-based sensor overcomes the limitations of current methods that rely on biofluid samples, such as blood, urine and sweat. This makes it a promising alternative for wearable, continuous, and real-time health monitoring, facilitating the early detection of conditions such as cardiovascular diseases and stroke.

New research identifies biomarkers that link alcohol use disorder and Alzheimer disease

Researchers agree that alcohol use can produce global and regional tissue volume changes in the brain, and that excessive alcohol use is associated with dementia and cognitive decline. A new study has examined the relationship between Alzheimer disease – the most common type of dementia – and alcohol use disorder (AUD), discovering biomarkers that link the two.

NIH awards $3.4M to Wayne State University to investigate biomarkers for better reproductive success

A new $3.4 million award to the Wayne State University School of Medicine from the National Institutes of Health aims to overcome the limitations of conventional semen analyses by examining mitochondrial DNA levels in sperm as a novel biomarker of sperm fitness.

MD Anderson Research Highlights for March 7, 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Study: Misfolded alpha-synuclein protein key to early detection of Parkinson’s disease

The presence of a misfolded alpha-synuclein protein can be used to determine if people have Parkinson’s disease, according to a new study using technology developed by a researcher at UTHealth Houston. This biomarker could pave the way for the development of better diagnostic tools and new treatment options for the disease.

Landmark Study of Biomarker Data May Enable Better Treatment for Early Onset Dementia

In a study publishing in Nature Medicine on September 22, 2022, University of California San Francisco researchers Adam Staffaroni, PhD, and Adam Boxer, MD, PhD, combined and harmonized clinical, neuroimaging, and fluid biomarkers from nearly all familial FTD clinical research participants across North America and Europe. With that data, they developed models of clinical and biomarker dynamics to determine the temporal sequence of biomarker and clinical changes in f-FTD before disease progression begins.

Research links red meat intake, gut microbiome, and cardiovascular disease in older adults

A new study shows older adults who ate about a serving of meat daily had a 22 percent higher risk of cardiovascular disease than those who didn’t eat meat, and identifies biologic pathways that help explain the risk. Higher risk and links to gut bacteria were found for red meat, not poultry, eggs, or fish.

MD Anderson Research Highlights for July 13, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.

Moffitt Researchers Identify Splice Variant Biomarkers in Clear Cell Renal Cell Carcinoma

Scientists are trying to improve their understanding of the development of clear cell renal cell carcinoma to develop new targeted therapeutics. In a new study published in European Urology, Moffitt Cancer Center researchers identify biomarkers for this disease type and develop a tool to indicate which patients are at high risk of poor outcomes based on their biomarker expression.

Study of promising Alzheimer’s marker in blood prompts warning about brain-boosting supplements

Elevated levels of an enzyme called PHGDH in the blood of older adults could be an early warning sign of Alzheimer’s disease. Research led by UC San Diego has consistently found high levels of PHGDH expression in brain tissue and blood samples of older adults with different stages of the disease.

Pituitary Reproductive Regulatory Factors, Mercury Levels, and More Featured in November 2021 Toxicological Sciences

In the November 2021 issue, Toxicological Science features leading toxicology research in areas such as biomarkers, carcinogenesis, and environmental toxicology.

Genetic biomarker test predicts recurrence and survival outcomes for men with high-risk prostate cancer

A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Potential biomarker found for lung disease in scleroderma patients

Researchers have discovered a protein that may predict disease severity for scleroderma-associated interstitial lung disease, the leading cause of death for patients with the rare autoimmune condition. Higher circulating levels of the CTRP9 were associated with more severe lung disease, while low levels were associated with preserved function.

Epitranscriptomics, Xenobiotic Nuclear Receptors, Arsenic Exposure, and More Featured in May 2021 Toxicological Sciences

Research on biomarkers, carcinogenesis, regulatory science, and more is available in the latest issue of Toxicological Sciences.

Newly Identified Pathway, Biomarkers May Be Tools to Prevent Kidney Injury-induced Lung Damage

Article title: Altered lung metabolism and mitochondrial DAMPs in lung injury due to acute kidney injury Authors: Mark Hepokoski, Jing Wang, Kefeng Li, Ying Li, Purva Gupta, Tina Mai, Alex Moshensky, Mona Alotaibi, Laura E. Crotty Alexander, Atul Malhotra, Prabhleen Singh…

Roswell Park Researchers Identify New Biomarker of Response to Checkpoint Inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy. This discovery, published today in the journal Nature Communications, is not only an important step forward in lung cancer treatment, but also has implications for other malignancies, according to lead author Fumito Ito, MD, PhD, FACS.

T Cell Therapy, Gut Microbiome, Tumorigenicity, and More Featured in September 2020 Toxicological Sciences

Toxicological Sciences features leading research in toxicology in the areas of biomarkers, environmental toxicology, and more in the September 2020 issue.

Researchers make significant step toward blood test for Alzheimer’s disease

Researchers at Washington University School of Medicine in St. Louis have developed a technique to detect minute amounts of a protein fragment linked to Alzheimer’s disease in the blood. The study, which will be published July 28 in the Journal of Experimental Medicine (JEM), shows that levels of p-tau-217 are elevated during the early stages of Alzheimer’s disease and could lead to a simple blood test capable of diagnosing the neurodegenerative disorder years before any symptoms begin to appear.